Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...

Research analysts at Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating ...

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...

Guggenheim initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price target Discover the Best Stocks and Maximize Your ...

Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of February ...

Fintel reports that on February 19, 2025, Piper Sandler initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Overweight recommendation. Analyst Price Forecast Suggests 232.44% Upside As ...

Shares of Compass Therapeutics stock opened at $3.38 on Wednesday. The firm has a market cap of $465.05 million, a P/E ratio of -9.13 and a beta of 1.17. Compass Therapeutics has a 12 month low of ...

Compass Therapeutics, Inc. (CMPX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its pipeline development programs and current cash position. The phenomenal ...